Ascendis PharmaASND
About: Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Employees: 1,017
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
27% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 66
1.78% more ownership
Funds ownership: 104.07% [Q3] → 105.84% (+1.78%) [Q4]
3% less funds holding
Funds holding: 218 [Q3] → 211 (-7) [Q4]
6% less capital invested
Capital invested by funds: $9.33B [Q3] → $8.78B (-$549M) [Q4]
10% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 39
18% less funds holding in top 10
Funds holding in top 10: 17 [Q3] → 14 (-3) [Q4]
64% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $32.7M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
JP Morgan Jessica Fye 69% 1-year accuracy 27 / 39 met price target | 19%upside $200 | Overweight Maintained | 18 Mar 2025 |
Cantor Fitzgerald Li Watsek 26% 1-year accuracy 11 / 43 met price target | 19%upside $200 | Overweight Maintained | 25 Feb 2025 |
Evercore ISI Group Josh Schimmer 22% 1-year accuracy 12 / 55 met price target | 55%upside $260 | Outperform Maintained | 18 Feb 2025 |
Goldman Sachs Paul Choi 50% 1-year accuracy 5 / 10 met price target | 34%upside $225 | Buy Maintained | 13 Feb 2025 |
UBS Eliana Merle 25% 1-year accuracy 5 / 20 met price target | 17%upside $196 | Buy Initiated | 7 Jan 2025 |
Financial journalist opinion









